Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-11006 + Chemotherapy in Recurrent Osteosarcoma and Ewing's Sarcoma
NCT04183062Phase 2Withdrawn
- Sponsor
- Nicklaus Children's Hospital
- Start
- Oct 2019
- Primary completion
- Oct 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BIO-11006 in osteosarcoma (OS) and Ewing sarcoma, sponsored by Nicklaus Children's Hospital. Primary endpoint: Treatment-emergent adverse events up to 16 months. Planned start Oct 2019; status: withdrawn.
02
Drugs
BIO-11006
03
Conditions
osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on NCT04183062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183062.